INSM
Insmed Incorporated
INSM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
INSM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
INSM's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
INSM PE Valuation
INSM has no meaningful PE right now: it lost money over the past year.
INSM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect INSM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
INSM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.83 | +$3.34 |
| Q2 2026 | -$4.12 | +$1.57 |
| Q1 2026 | -$5.76 | +$0.17 |
| Q4 2025 | -$6.42 | -$0.85 |
| Q3 2025 | -$6.17 | -$0.62 |
| Q2 2025 | -$5.69 | -$0.30 |
| Q1 2025 | -$5.93 | -$0.70 |
| Q4 2024 | -$5.57 | -$0.23 |
INSM lost $2.83 per share over the past year, a smaller loss than the year before.
INSM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $524.4M | +268% |
| Q2 2026 | $425.5M | +296% |
| Q1 2026 | $306M | +230% |
| Q4 2025 | $263.8M | +153% |
| Q3 2025 | $142.3M | +52% |
| Q2 2025 | $107.4M | +19% |
| Q1 2025 | $92.8M | +23% |
| Q4 2024 | $104.4M | +25% |
INSM's revenue has grown year over year for 23 quarters in a row: $524M last quarter, up 268% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -17% | +240 points |
| Q2 2026 | -0.4% | +291 points |
| Q1 2026 | -50% | +217 points |
| Q4 2025 | -121% | +99 points |
| Q3 2025 | -257% | -29 points |
| Q2 2025 | -291% | +29 points |
| Q1 2025 | -267% | -75 points |
| Q4 2024 | -221% | -7.6 points |
INSM's operating margin was −17% last quarter, up 240 points from the same quarter a year ago, near the top of its range since 2019.
INSM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.1M | +$180.1M |
| Q2 2026 | -$95.1M | +$114M |
| Q1 2026 | -$226.2M | +$45.9M |
| Q4 2025 | -$264.2M | -$61.4M |
| Q3 2025 | -$222.2M | -$37.6M |
| Q2 2025 | -$209.1M | -$79.3M |
| Q1 2025 | -$272.2M | -$83.4M |
| Q4 2024 | -$202.8M | -$69.8M |
INSM has burned cash in almost every quarter: −$628M over the past year, against −$906M the year before.
INSM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.4M shares |
| 1 year | +3.3% | +7M shares |
| 3 years | +53% | +75.9M shares |
| 5 years | +87% | +102M shares |
| Available history | +159% | +134M shares |
INSM has 219M diluted shares, up 3.3% from a year ago.
INSM Net Leverage
INSM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INSM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 50.6 | Neutral |
INSM's weekly RSI is 51 (neutral) and its Stochastic is 51 (neutral).
INSM PE vs Healthcare Sector
INSM has no meaningful PE right now: it lost money over the past year.
INSM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $108.0 | 9.3% above |
| 20 week MA | $114.0 | 3.6% above |
| 50 week MA | $131.6 | 10% below |
| 100 week MA | $119.3 | 1% below |
| 200 week MA | $78.3 | 51% above |
INSM's trend is mixed: it's above three of its five weekly moving averages, and 51% above its 200-week average.
INSM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.7 | $35.4 | +49% |
| 2021 | $35.4 | $28.3 | -20% |
| 2022 | $28.3 | $19.4 | -32% |
| 2023 | $19.4 | $31.0 | +60% |
| 2024 | $31.0 | $69.6 | +125% |
| 2025 | $69.6 | $177.9 | +156% |
| 2026 YTD | $177.9 | $118.1 | -34% |
INSM is down 34% so far in 2026, after finishing higher in four of the previous six years.